Metraipolis › archive › dc_b5261eecab31

Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: a systematic review and meta-analysis of… — Europe PMC PMID:41635538

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41635538
DOI
10.3389/fendo.2025.1732708
License (as archived)
solo-consultazione
Archived
2026-11-06T17:20:45.547Z
SHA-256 of the archived text
50d4e2944d0c5662a2eb004042a052c814ae6fbbb9ce13b86c7f7c777613761c
Stable URL of this page
https://metraipolis.com/documento/dc_b5261eecab31

How to cite

Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: a systematic review and meta-analysis of… — Europe PMC PMID:41635538 — Europe PMC (en), https://europepmc.org/article/MED/41635538 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b5261eecab31 (Metraipolis archive dc_b5261eecab31, sha256 50d4e2944d0c5662a2eb004042a052c814ae6fbbb9ce13b86c7f7c777613761c)
BibTeX
@misc{dcb5261eecab31,
  title = {Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: a systematic review and meta-analysis of… — Europe PMC PMID:41635538},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41635538},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b5261eecab31; sha256 50d4e2944d0c5662a2eb004042a052c814ae6fbbb9ce13b86c7f7c777613761c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41635538. Agents can read the archived copy with the MCP tool read_document.